Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04181138 · ClinicalTrials.gov registry record

Primary Sclerosing Cholangitis in Children

A clinical trial of Liver Diseases and Primary Sclerosing Cholangitis, sponsored by Arbor Research Collaborative for Health.

Recruiting
Registry status
1,000
Enrollment target
12
Study locations

NCT04181138: Recruiting study of Liver Diseases and Primary Sclerosing Cholangitis, sponsored by Arbor Research Collaborative for Health.

NCT04181138 is a study of Liver Diseases and Primary Sclerosing Cholangitis that is actively recruiting participants, run by Arbor Research Collaborative for Health. The registered enrollment target is 1,000 participants, below the 61,128-participant average among 33 other Liver Diseases trials with a reported enrollment target (98% lower). The trial reports 12 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04181138, a study of Liver Diseases and Primary Sclerosing Cholangitis, is actively recruiting participants, sponsored by Arbor Research Collaborative for Health.

RECRUITING
Registry status
1,000 participants
Enrollment target
12
Study locations

Study Summary

Primary sclerosing cholangitis (PSC) is a rare liver disease that damages the liver's bile ducts. Bile ducts are tiny tubes that carry bile from the liver to the small intestine. Bile is a liquid produced by the liver that helps us absorb and use the nutrients in the food we eat. In people with PSC, the bile backs up into the liver and will damage it, causing scarring of the liver. The purposes of this study are to: * Collect medical and other data to learn more about PSC, how it progresses, and identify factors that may cause the disease to progress more quickly. * Ask questions about how PSC symptoms affect your child's life to learn more about its impact on your child's daily functioning * Children with PSC who are seen at one of the participating clinical sites in the Childhood Liver Disease Research Network (ChiLDReN) will be asked to contribute information, DNA, and other specimens. The information and specimens will be available to investigators to carry out approved research aimed at learning more about the possible causes and long-term effects of PSC.

Primary Outcome

Data will be collected on all phenotypes of PSC but attention is focused on how the intestinal inflammation and clinical activity of Inflammatory Bowel Disease (IBD) affect the progression of PSC, better classification of patients with features of Auto Immune Hepatitis (AIH), and the implications of bacterial cholangitis amongst all PSC phenotypes. Collection of retrospective clinical and laboratory data from the time of diagnosis of PSC and annual timepoints thereafter. Information regarding c

Study Locations (12)

Pennsylvania

  • The Children's Hospital of Philadelphia - Philadelphia
  • UPMC Children's Hospital of Pittsburgh - Pittsburgh

California

  • Children's Hospital of Los Angeles - Los Angeles

Colorado

  • Children's Hospital Colorado - Aurora

Georgia

  • Children's Healthcare of Atlanta - Atlanta

Illinois

  • Ann & Robert H Lurie Children's Hospital - Chicago

Indiana

  • Riley Hospital for Children - Indianapolis

Ohio

  • Cincinnati Children's Hospital Medical - Cincinnati

Texas

  • Texas Children's Hospital (Baylor College of Medicine) - Houston

Trial Details

FieldValue
Enrollment Target 1,000 participants
Start Date 2021-12-30
Est. Completion 2029-05-31

What NCT04181138 shows while recruiting

NCT04181138 is an observational study that tracks outcomes without assigning an intervention. Its 1,000 participants enrollment target places it among the larger protocols in the corpus, below the 61,128-participant average among 33 other Liver Diseases trials with a reported enrollment target (98% lower).

The record links to 3 conditions, with Liver Diseases appearing as the primary indexed condition, and to 0 interventions.

NCT04181138 lists 12 locations in 11 states (Pennsylvania, California, Colorado).

Frequently Asked Questions

What is clinical trial NCT04181138 about?

NCT04181138 is a clinical study titled "Primary Sclerosing Cholangitis in Children". Primary sclerosing cholangitis (PSC) is a rare liver disease that damages the liver's bile ducts. Bile ducts are tiny tubes that carry bile from the liver to the small intestine. Bile is a liquid produced by the liver that helps us absorb and use the nutrients in the food we eat. In people with PSC,...

What is the current status of trial NCT04181138?

This trial is currently recruiting. The enrollment target is 1,000 participants. The study started on 2021-12-30. Estimated completion is 2029-05-31.

What conditions does trial NCT04181138 study?

This clinical trial studies the following conditions: Liver Diseases, Primary Sclerosing Cholangitis, Cholangitis, Sclerosing.

Who is sponsoring clinical trial NCT04181138?

This trial is sponsored by Arbor Research Collaborative for Health, which has 15 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04181138 being conducted?

This trial has 12 study locations across California, Colorado, Georgia, Illinois, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Liver Diseases

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT04181138's enrollment target sits among peer trials

1,000 7th of 33 higher than 26 of 33 other Liver Diseases trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Liver Diseases trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00018044 · 1,000 participants

    Study of Mycobacterial Infections

  • NCT01036581 · 1,000 participants · NA

    Advanced Functional and Structural MRI Techniques for Neuropharmacological Imaging

  • NCT01192048 · 1,000 participants

    Genetics of Congenital Heart Disease

  • NCT01553214 · 1,000 participants · Phase 4

    Improving White Blood Cell Collection From Healthy Donors

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT04181138, the US trial registry maintained by the National Library of Medicine. NCT04181138 (large enrollment · multi site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.